Hypertension associated with therapies to treat arthritis and pain

Hypertension

Volumn 44, Issue 2, 2004, Pages 123-124

  White, William B ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTERIAL PRESSURE; ARTHRITIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DOSE RESPONSE; EDITORIAL; ENZYME INHIBITION; HUMAN; HYPERTENSION; PAIN; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; HEART DISEASES; HUMANS; HYPERTENSION; KIDNEY DISEASES; LACTONES; OSTEOARTHRITIS; PAIN; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 3542998087     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000136129.18326.26     Document Type: Editorial

References (17)

1. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000;284:1247-1255.
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
3. McAdam BF, Catella LF, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 [published erratum appears in Proc Natl Acad Sci U S A. 1999 May 11;96:5890]. Proc Natl Acad Sci U S A. 1999;96:272-277.
4. McAdam BF, Catella LF, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 [published erratum appears in Proc Natl Acad Sci U S A. 1999 May 11;96:5890]. Proc Natl Acad Sci U S A. 1999;96:272-277.
5. Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, Breedveld FC, Brune K, Burmester GR, Crofford LJ, Dougados M, DuBois RN, Fitzgerald GA, Frishman W, Garcia Rodriguez LA, Hochberg MC, Kalden JR, Laine L, Langman MJ, Prescott SM, van de Putte LB, Whelton A, White WB, Williams GH. Controversies in COX-2 selective inhibition. J Rheumatol. 2002;29:1501-1510.
6. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens. 2000;13:1161-1167.
7. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477-484.
8. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? Ann Intern Med. 1994;121:289-300.
9. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90: 959-963.
10. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39:929-934.
11. Sowers J, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen J, Fort J. The effects of cyclooxygenase-2 inhibitors and nonsteroidal antiinflammatory therapy on 24-hour blood pressure in hypertensive patients with osteoarthritis and type 2 diabetes mellitus. J Am Coll Cardiol. 2003;41:320A.
12. Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther. 2002; 72:50-61.
13. Solomon DH, Schneeweiss S, Levin R, Avorn J. The relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140-145.
14. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109: 2068-2073.
15. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Clinical advisory statement. Hypertension. 2000;35: 1021-1024.
16. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.
17. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004;43:525-530.